Venaxis Inc news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

APPY 1.92 -0.01 (-0.52%)
price chart
First Call Rating Update on Venaxis Inc
Venaxis Inc (NASDAQ:APPY): First Call has rated the counter a Strong Buy. The rating recommendation was disclosed in the First Call research information.
Venaxis, Inc. (APPY) Files Response with FDA Following Additional Information ...
Venaxis, Inc. (Nasdaq: APPY) announced it has filed its response to the FDA's Additional Information (AI) request related to the Company's APPY1 direct de novo submission.
Related articles »  
Venaxis, Inc. (APPY) in Focus: Stock Adds 7.6% in Session
Venaxis, Inc. was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session.
Related articles »  
Monday Stock Updates: Cleco Corp , Venaxis Inc , Glacier Bancorp Inc
Venaxis Inc (APPY) erased 0.52% or 0.01 points from its share value in todays trading session. The bulls did try to put up a fight and stock hit 2.03 after opening the day at 1.96 but eventually caved in to the extreme selling pressure and closed at 1.92.
Short Interest of Venaxis Inc Drops by 2.9%
Venaxis Inc (NASDAQ:APPY) stated loss of 45,421 shares or 2.9% in the short interest. The short interest registered from 1,568,545 on December 15,2014 to 1,523,124 on December 31,2014.
Venaxis Inc (APPY) news: What Every Investor Needs To Know About Venaxis, Inc.
Computed tomography imaging is used to diagnose approximately 35% of these cases, but comes with a heavy radioactive price tag. Accuracy of computer tomography imaging is measured at 93-98%.
Venaxis: Latest Clinical Data Reveals Huge Market Potential (APPY)
Venaxis Inc. recently reported detailed data of the clinical pathways undertaken by the pediatric patients enrolled in their pivotal trial.
Venaxis to Present at Canaccord Genuity 2014 Medical Technologies ...
13, 2014 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1� Test, a rapid blood test for aiding in identifying children, adolescent, and young ...
Related articles »  
Venaxis Inc (APPY) news: Venaxis's Pivotal Data Due In March
(Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap.
Related articles »  
Venaxis Inc (APPY) news: Venaxis expects APPY1 approval following positive ...
Venaxis' (APPY) APPY1 Test for identifying patients who are at low risk of appendicitis performed well in a pivotal trial, with sensitivity and negative predictive value results surpassing those in a pilot study.